recombinant l-ifn adenovirus injection
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05180851)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05914935 | Early Phase 1 (Phase 1) | Jun 27, 2023 | Fujian Medical University, Government of China |
| NCT05180851 | Early Phase 1 (Phase 1) | Nov 30, 2021 | Government of China, Shanghai Fengxian District Central Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 0 | 1 | 2021 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Shanghai Fengxian District Central Hospital | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1